Clinical trial · Observational
The Relationship Between Microsatellite Instability and Efficacy of Fluorouracil Based Adjuvant Chemotherapy in Gastric Cancer After Operation
NCT03485196CI-TRIAL-00060245completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The relationship between Microsatellite instability and efficacy of fluorouracil based adjuvant chemotherapy in gastric cancer after operation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Microsatellite instability | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- MSI-H group
- description
- We use the immunohistochemical expression of mismatch repair proteins (MutS protein homolog 2( MSH2),MutS protein homolog 6( MSH6) and PMS2（postmeiotic segregation increased 2 ）) to Determine the MSI status . When one antibodies or more show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite instability high (MSI-H).
- interventionNames
- Other: Microsatellite instability
- label
- MSI-L group
- description
- We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSI-L).
- interventionNames
- Other: Microsatellite instability
- label
- MSS group
- description
- We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSS).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histopathology or cytopathology proven gastric cancer; 2. Operable advanced gastric cancer patients: primary lesions can be completely excision, no distant metastasis; 3. Postoperative patients who can tolerate 5-FU based (5-FU，S-1 or Capecitabine) adjuvant chemotherapy; 4. Life expectancy of at least 6 months; 5. ECOG（Eastern Cooperative Oncology Group ） score 0-1; 6. Age: 18\~80 years old; 7. Normal hemodynamic indices before the recruitment (including blood cell count and liver/kidney function). * For example: WBC（White blood cell count ）\>4.0×109/L; NEU（Neutrophils）\>1.5×109/L; PLT（Platelet）\>100×109/L; 8. Roughly normal cardiopulmonary function: No coronary heart disease, myocardial infarction, pulmonary heart disease, refractory hypertension; 9. Not concomitant with other uncontrollable benign diseases before the recruitment; 9\. Voluntarily signed the informed consent. Exclusion Criteria: 1. Advanced gastric cancer patients with distant metastasis and inoperable ; 2. Patients who cannot tolerate 5-FU based adjuvant chemotherapy; 3. Pregnant or lactating women; 4. Patients who have no desire to participate in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.